Relvar Ellipta cuts exacerbations in real-world COPD study

GlaxoSmithKline plc(LSE:GSK; NYSE:GSK) and partner Innoviva Inc. (NASDAQ:INVA) said Relvar Ellipta fluticasone furoate/vilanterol met the primary endpoint in the Phase IIIb Salford Lung Study, a real-world outcomes trial, to treat chronic obstructive

Read the full 328 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE